Johnson & Johnson Vision Care Ireland UC – FDA 483, Feb 15, 2022
An FDA inspection of Johnson & Johnson Vision Care Ireland US in Limerick, Ireland, a combination drug/device manufacturer, identified 12 significant deficiencies. These issues span inadequate manufacturing process controls, critical data integrity failures in laboratory and electronic records, and a lack of robust quality unit oversight. The firm also demonstrated weaknesses in its CAPA processes, supplier management, and employee GMP training, indicating systemic non-compliance with cGMP requirements.
ID · c3cbfcf5-1ee2-45d6-9102-d2c03f0b7eff
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.